Sign inJoin waitlistJoin the waitlist

Lorinda Chung

Associate Program Director for Rheumatology Fellowship, Stanford University · Stanford Health Care

Credentials: · · · ·

History

Rheumatology, Stanford University Fellowship · Stanford Health Care
Present
Internal Medicine Residency Support Group · Stanford Health Care
Present
Stanford Health Care
Present

Stanford University Immunology and Rheumatology Fellowship (2006) CA
2004–2006
Stanford University
2000–2003
University School of Public Health
Ohio State University College of Medicine
1996–2000

Research

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative
Arthritis & Rheumatism · 2013 · 2,564 citations
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
The Lancet · 2016 · 527 citations
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study
Journal of the American Academy of Dermatology · 2011 · 443 citations

David Fiorentino
65 papers
Dinesh Khanna
59 papers
Virginia Steen
53 papers
Tracy Frech
35 papers
Jessica Gordon
33 papers
Daniel Furst
30 papers
Maureen Mayes
29 papers
Robyn Domsic
25 papers
Vivien Hsu
25 papers
Ami Shah
23 papers
Laura Hummers
23 papers
Elana Bernstein
22 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $114 · Stanford University
2007–2008

Clinical trials

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Principal investigator · Recruiting · Phase 1
Stanford University
2024–2039
Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Principal investigator · Completed · Phase 2
Stanford University
2016–2020
A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
Principal investigator · Completed
Stanford University
2008–2010
Imatinib in Systemic Sclerosis
Principal investigator · Completed · Phase 1, Phase 2
Stanford University
2007–2010